Navigation Links
Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Date:8/19/2007

hich should not be given to healthy volunteers, this evaluation is being done in previously untreated elderly patients with de novo poor-risk AML who receive Cloretazine(R) (VNP40101M) therapy.

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. A Phase II trial of Cloretazine(R) (VNP40101M) in small cell lung cancer is also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. In preclinical studies, Vion is also evaluating VNP40541, a hypoxia-selective compound, and hydrazone compounds. The Company also is seeking development partners for TAPET(R), its modified Salmonella vector used to deliver anticancer agents directly to tumors. For additional information on Vion and its product development programs, visit the Company's Internet web site at http://www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to obtain regulatory approval for its products, delayed or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies or clinical trials are not predictive of safety and efficacy results in later clinical trials, the need for additional research and testing, the potential inability to secure external sources of funding to continue operations, the inability to access capital and f
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... , March 5, 2015  Medical Diagnostic Laboratories, ... in high complexity, state-of-the-art, automated DNA-based molecular analyses, ... Papillomavirus (HPV) testing which utilizes cutting edge technology, ... Each year, approximately 12,000 women are diagnosed with ... . Genital Human Papillomaviruses (HPV) are a ...
(Date:3/5/2015)...  AMRI (NASDAQ: AMRI ) announced today ... position of VP of International Sales, effective immediately. He ... of Global Sales and Marketing. In ... team in an effort to increase worldwide customer value ... Pettersson will drive strategy for sales and marketing efforts ...
(Date:3/5/2015)... March 5, 2015 LUNGevity Foundation, the ... and Drug Administration,s (FDA) approval of Bristol Myers ... other immunotherapy treatments add another critical new treatment ... power of a patient,s own immune system to ... approved specifically for patients with squamous cell lung ...
Breaking Medicine Technology:Medical Diagnostic Laboratories, L.L.C., the Institute for Biomarker Research Announces New HPV Tests 2Medical Diagnostic Laboratories, L.L.C., the Institute for Biomarker Research Announces New HPV Tests 3AMRI Hires VP of International Sales 2LUNGevity Foundation Applauds FDA Approval of Immunotherapy Drug Opdivo 2LUNGevity Foundation Applauds FDA Approval of Immunotherapy Drug Opdivo 3
... /PRNewswire-iReach/ -- The iMPak Health Journal for ... before and after their prescribed medication regimen, providing physicians ... for Pain provides a consumer engaged method for date ... both long-acting and short medications not readily seen before. ...
... 10, 2012  RSB Spine, LLC, today announced allowance ... its line of InterPlate® cervical and lumbar intervertebral ... a privately held medical device company. News releases ... on the Internet at: www.rsbspine.com ...
Cached Medicine Technology:HealthSaaS Inc. with iMPak Health and Meridian Health Announce Integrated Pain Management and Medication Adherence Solution 2HealthSaaS Inc. with iMPak Health and Meridian Health Announce Integrated Pain Management and Medication Adherence Solution 3
(Date:3/5/2015)... 2015 Wimbledon Health Partners , ... echocardiogram and NCV testing, announced the addition ... Medical Officer. Dr. Artel will be responsible for medical ... WimbledonMED program and the continued growth and support of ... with Wimbledon Health Partners as a consulting physician since ...
(Date:3/5/2015)... The recent influx of online diet pills ... more and more internet ads offering “prescription” online diet ... easy for more people to fall prey to gimmicks ... their health. The company urges consumers to ask themselves ... , 1.    Where are the products manufactured and are they ...
(Date:3/5/2015)... T.E.N., a technology and information security ... winners Thursday evening, March 4, at the 2015 ... the Westin Buckhead in Atlanta, GA. , ... selected as the Information Security Executive® of the ... Pete is an industry veteran with over 15 ...
(Date:3/5/2015)... Considering egg freezing? Atlanta Center for ... an informational event on March 30, where ... families with egg freezing. , What: Egg Freezing Cocktail ... Atlanta, GA, Time: 5:30 - 7:30 PM, Date: Monday, ... here ! , In response to the growing ...
(Date:3/5/2015)... What makes a legend? In the case of renowned ... of exceptional courtroom performance, championing big causes and underdogs alike ... brilliant service, the Dallas Bar Association has named Schmidt a ... at a luncheon on Tuesday, April 7, 2015 at 12 ... nominees for this year are Bob Vial, Deborah Hankinson and ...
Breaking Medicine News(10 mins):Health News:Wimbledon Health Partners Appoints Chief Medical Officer to Attain Medicare Market Share 2Health News:Wimbledon Health Partners Appoints Chief Medical Officer to Attain Medicare Market Share 3Health News:Diet Doc Announces Four Simple Questions that Dieters Must Ask Prior to Purchasing Online Diet Pills 2Health News:Diet Doc Announces Four Simple Questions that Dieters Must Ask Prior to Purchasing Online Diet Pills 3Health News:Pete Chronis of EarthLink and Jabil Claim Top Awards at ISE® Southeast 2Health News:Pete Chronis of EarthLink and Jabil Claim Top Awards at ISE® Southeast 3Health News:Pete Chronis of EarthLink and Jabil Claim Top Awards at ISE® Southeast 4Health News:Egg Freezing Seminar Allows Women to Pause the Biological Clock for Age, Social or Medical Reasons 2Health News:Egg Freezing Seminar Allows Women to Pause the Biological Clock for Age, Social or Medical Reasons 3Health News:C.L. Mike Schmidt Named "Legend In Trial Law" by Dallas Bar Association 2
... is not the primary factor for causing metabolic syndrome ... leading to a cluster of conditions that includes the ... high blood pressure, and changes in cholesterol. ... us carry has long been linked to metabolic syndrome, ...
... As Kerala staggers under the whipping rod ... has been cornered over its quest for a 'politically ... Incidentally, the Left Democratic Front (LDF) government had dumped ... ICICI Lombard to seek out a cost-competitive, quality-competitive public ...
... payout when the Los Angeles archdiocese agreed to an out-of-court ... ,Divided by the 508 plaintiffs, the $660 million deal ... the actual payouts will fluctuate considerably, with some victims receiving ... And that's before lawyers take their cut. ,Determining ...
... Urgent action is needed to address gender barriers to ... today ,Key findings from the year-long Women ... BMA conference. A preliminary report states that: ... particularly at senior levels. Only two out of all ...
... it or not, Kapila, an impregnated cow of Sarnagat in ... age of two without ever getting crossed with a stud ... now. ,According to the cows owner Sardar Ajit ... and that too without ever getting pregnant. ,Kapila ...
... Welfare Minister Anbumani Ramadoss on Tuesday said that the health ... developing nation . ,In his opening remarks at ... National Rural Health Mission (NRHM), Ramadoss said: The country is ... keep up with the requirements of the working class. The ...
Cached Medicine News:Health News:Study Finds Abdominal Fat Not the Prime Cause for Metabolic Syndrome 2Health News:Kerala Government Battles With Chikungunya On All Counts 2Health News:Sexual Abuse Payout Re-opens Old Wounds 2Health News:Sexual Abuse Payout Re-opens Old Wounds 3Health News:Female Doctors Facing Barriers to Careers in Education and Research, Study Finds 2
Inquire...
... UltraPure™ Agarose resolves DNA and RNA fragments ... UltraPure™ Agarose is a standard melting temperature ... separation analysis. Its high gel strength ... during handling nor during Southern and Northern ...
Agarose IEF is suitable for isoelectric focusing of large molecules and is the gel of choice for many IEF applications and immunochemical detection methods....
... molecular biology grade, standard melting temperature agarose that ... DNA, RNA, and PCR products = 1 kb. ... processing and blotting. Performance testing of NuSieve 3:1 ... to 1,000 bp, though this agarose is capable ...
Medicine Products: